使用控制图监测手术结局以减少患者主要不良事件:整群随机试验
该研究为法国多中心整群随机试验,纳入155 362例成人消化道手术患者,20个外科中心接受控制图监测结局并定期反馈指标,20个中心仅常规护理。干预组主要不良事件(住院死亡、ICU入住、再手术、严重并发症)绝对风险降低0.9%(95%CI 0.4%至1.4%),NNT为114(70至280)。校正后主要不良事件比值比0.89(95%CI 0.83至0.96),患者死亡0.84(0.71至0.99),ICU入住0.85(0.76至0.94),再手术0.91(0.82至1.00),严重并发症无显著变化(0.96,0.87至1.07)。干预实施依从性高的医院效果更显著。
要点
- 对消化道手术团队实施控制图监测结局并定期反馈指标,可使30天内主要不良事件绝对风险降低0.9%(95%CI 0.4%至1.4%),NNT=114(70至280)。
- 干预组患者死亡校正后比值比0.84(95%CI 0.71至0.99),ICU入住0.85(0.76至0.94),再手术0.91(0.82至1.00),严重并发症无显著变化(0.96,0.87至1.07)。
- 效果与干预实施程度成比例:高度依从医院的主要不良事件比值比0.84(0.77至0.92),死亡0.78(0.63至0.97),ICU入住0.76(0.67至0.87),再手术0.84(0.74至0.96)。
- 干预措施包括每季度提供控制图反馈、建立研究冠军伙伴关系(外科医生和另一名团队成员)、培训团队会议、张贴海报、维护日志和制定改进计划。
- 该干预可减少消化道手术患者术后主要不良事件,但严重并发症未显著减少,需关注干预实施的依从性。
适用人群与场景
- 法国40个外科中心的成人(155 362例)消化道手术患者,干预组75 047例(实施前37 579例,实施后37 468例),对照组80 315例(41 548例和38 767例)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 第一步:在干预医院建立研究冠军伙伴关系,由一名外科医生和另一名手术团队成员(外科医生、麻醉师或护士)组成。
- 第二步:对团队成员进行培训,以开展团队会议、在手术室张贴海报、维护日志并制定改进计划。
- 第三步:每季度提供一套控制图,对结局进行前瞻性监测,并定期反馈指标。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:全国性、平行、整群随机试验,嵌入双重差分分析;40个法国外科中心,155 362例成人消化道手术患者。
- 干预:20个中心接受控制图前瞻性监测结局并定期反馈指标,20个中心仅常规护理。
- 主要终点:30天内主要不良事件复合终点(住院死亡、ICU入住、再手术、严重并发症);干预组绝对风险降低0.9%(95%CI 0.4%至1.4%),NNT=114(70至280)。
- 校正后主要不良事件比值比0.89(95%CI 0.83至0.96),患者死亡0.84(0.71至0.99),ICU入住0.85(0.76至0.94),再手术0.91(0.82至1.00),严重并发症0.96(0.87至1.07)。
- 高度依从医院的主要不良事件比值比0.84(0.77至0.92),死亡0.78(0.63至0.97),ICU入住0.76(0.67至0.87),再手术0.84(0.74至0.96)。
证据类型、等级与局限
- 证据类型:整群随机试验(RCT);局限性:整群设计、干预实施程度不一、严重并发症无显著减少。
对床旁实践的改变
- 在消化道手术团队中实施控制图监测结局并定期反馈指标,可减少主要不良事件、患者死亡和ICU入住,但对严重并发症无显著影响。
- 效果与干预实施依从性相关,高度依从的医院获益更明显,提示需确保团队会议、海报、日志和改进计划等落实。
- 该干预适用于成人消化道手术患者,不适用于其他手术类型或非成人人群(原文未提及其他人群)。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT02569450。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the effect of introducing prospective monitoring of outcomes using control charts and regular feedback on indicators to surgical teams on major adverse events in patients.
DESIGN: National, parallel, cluster randomised trial embedding a difference-in-differences analysis.
SETTING: 40 surgical departments of hospitals across France.
PARTICIPANTS: 155 362 adults who underwent digestive tract surgery. 20 of the surgical departments were randomised to prospective monitoring of outcomes using control charts with regular feedback on indicators (intervention group) and 20 to usual care only (control group).
INTERVENTIONS: Prospective monitoring of outcomes using control charts, provided in sets quarterly, with regular feedback on indicators (intervention hospitals). To facilitate implementation of the programme, study champion partnerships were established at each site, comprising a surgeon and another member of the surgical team (surgeon, anaesthetist, or nurse), and were trained to conduct team meetings, display posters in operating rooms, maintain a logbook, and devise an improvement plan.
MAIN OUTCOME MEASURES: The primary outcome was a composite of major adverse events (inpatient death, intensive care stay, reoperation, and severe complications) within 30 days after surgery. Changes in surgical outcomes were compared before and after implementation of the programme between intervention and control hospitals, with adjustment for patient mix and clustering.
RESULTS: 75 047 patients were analysed in the intervention hospitals (37 579 before and 37 468 after programme implementation) versus 80 315 in the control hospitals (41 548 and 38 767). After introduction of the control chart, the absolute risk of a major adverse event was reduced by 0.9% (95% confidence interval 0.4% to 1.4%) in intervention compared with control hospitals, corresponding to 114 patients (70 to 280) who needed to receive the intervention to prevent one major adverse event. A significant decrease in major adverse events (adjusted ratio of odds ratios 0.89, 95% confidence interval 0.83 to 0.96), patient death (0.84, 0.71 to 0.99), and intensive care stay (0.85, 0.76 to 0.94) was found in intervention compared with control hospitals. The same trend was observed for reoperation (0.91, 0.82 to 1.00), whereas severe complications remained unchanged (0.96, 0.87 to 1.07). Among the intervention hospitals, the effect size was proportional to the degree of control chart implementation witnessed. Highly compliant hospitals experienced a more important reduction in major adverse events (0.84, 0.77 to 0.92), patient death (0.78, 0.63 to 0.97), intensive care stay (0.76, 0.67 to 0.87), and reoperation (0.84, 0.74 to 0.96).
CONCLUSIONS: The implementation of control charts with feedback on indicators to surgical teams was associated with concomitant reductions in major adverse events in patients. Understanding variations in surgical outcomes and how to provide safe surgery is imperative for improvements.
TRIAL REGISTRATION: ClinicalTrials.gov NCT02569450.
参考来源
- Duclos A, Chollet F, Pascal L, et al. Effect of monitoring surgical outcomes using control charts to reduce major adverse events in patients: cluster randomised trial. BMJ. 2020. PMID: 33148601. doi:10.1136/bmj.m3840
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。